{"id":27979,"date":"2025-06-10T10:12:12","date_gmt":"2025-06-10T04:42:12","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=27979"},"modified":"2025-06-11T10:12:32","modified_gmt":"2025-06-11T04:42:32","slug":"bispecific-and-trispecific-antibodies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies","title":{"rendered":"Bispecific and Trispecific Antibodies: Are They Better Than CAR-Ts?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69deb168b370f\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69deb168b370f\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies\/#Target_Patient_Pool_for_Bispecific_and_Trispecific_Antibodies\" >Target Patient Pool for Bispecific and Trispecific Antibodies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies\/#Bispecific_Antibodies_Bridging_the_Gap\" >Bispecific Antibodies: Bridging the Gap<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies\/#Promising_Bispecific_and_Trispecific_Antibodies_in_the_Pipeline\" >Promising Bispecific and Trispecific Antibodies in the Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies\/#Bispecific_and_Trispecific_Antibodies_Future_Directions\" >Bispecific and Trispecific Antibodies: Future Directions<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>CAR-T cell therapy has revolutionized the treatment of blood cancers, earning regulatory approval and delivering impressive results in hematologic malignancies. However, its success has not yet translated to solid tumors, where it continues to face significant challenges and limited long-term efficacy. As a result, <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-pipeline-insight\">ongoing CAR-T development<\/a> remains largely focused on blood cancers.<\/p>\n\n\n\n<p>In contrast, bispecific antibodies have emerged as a versatile and promising class of therapeutics, securing approvals for both blood cancers and solid tumors. Notably, they have shown more consistent and durable responses in solid tumor settings. Current research and development in the bispecific antibody space increasingly target solid tumors, driven by their favorable clinical outcomes and broader applicability.<\/p>\n\n\n\n<p>Moreover, the \u201c<em>off-the-shelf<\/em>\u201d nature and relatively simpler manufacturing process of bispecific antibodies offer a clear advantage over the complex and personalized production of CAR-T therapies. This makes bispecific antibodies an attractive and scalable option in the evolving landscape of cancer immunotherapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-patient-pool-for-bispecific-and-trispecific-antibodies\"><span class=\"ez-toc-section\" id=\"Target_Patient_Pool_for_Bispecific_and_Trispecific_Antibodies\"><\/span>Target Patient Pool for Bispecific and Trispecific Antibodies<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In the 7MM, the highest eligible pool of promising indications for bispecific antibodies in <strong>oncology<\/strong> was seen in the United States, followed by EU4 and the UK in 2024. The treatment-eligible pool of potential indications for bispecific antibodies in oncology in the United States was around <strong>900K<\/strong> in 2024.<\/p>\n\n\n\n<p>As per the estimates, of the selected hematological indications in the 7MM in 2024, the patient pool for <strong>DLBCL <\/strong>and <strong>Multiple Myeloma<\/strong> is high. For example, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-lymphocytic-leukemia-all-market\">patient pool for <strong>Acute Lymphocytic Leukemia<\/strong><\/a> (ALL), a less prevalent type of leukemia that primarily affects children, is smaller. In 2024, among the solid cancers, <strong>NSCLC and Breast cancer<\/strong> have significantly larger patient pools due to their higher incidence in the United States.<\/p>\n\n\n\n<p>Numerous bispecific antibodies have received FDA approval, and Key Late-Stage (Registered, Phase III and II\/III) emerging bispecific players include AstraZeneca (Generalised Myasthenia Gravis), Zenas BioPharma (IgG4-related Disease, Relapsing Multiple Sclerosis [RMS], and Systemic Lupus Erythematosus [SLE]), Merus (Pancreatic Cancer and HNSCC), Regeneron (DLBCL, Follicular lymphoma), Sichuan Baili Pharmaceutical (NSCLC), Alphamab (Pancreatic), AstraZeneca (BTC, NSCLC, HNSCC), SystImmune (Nasopharyngeal), Biotheus (TNBC), and others<\/p>\n\n\n\n<p>Trispecific antibodies are a relatively uncharted territory with the majority of players such as Innovent Biologics (Multiple Myeloma), Merck (Multiple Myeloma and Neuroendocrine tumor), Genor Biopharma (NSCLC), Chimagen Biosciences (Non-Hodgkin&#8217;s lymphoma), Sanofi (Acute myeloid leukemia, Myelodysplastic syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia), Beijing Mabworks Biotech (Multiple Myeloma), Roche (Multiple Myeloma and Neuroendocrine tumor), Simcere Pharma (Multiple Myeloma), Johnson &amp; Johnson Innovative Medicine (CLL, NHL, Multiple Myeloma), Novartis, Chugai, Numab Therapeutics, and others, in early stage of development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bispecific-antibodies-bridging-the-gap\"><span class=\"ez-toc-section\" id=\"Bispecific_Antibodies_Bridging_the_Gap\"><\/span>Bispecific Antibodies: Bridging the Gap<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Bispecific antibodies are designed to address complex diseases by targeting two disease factors simultaneously within a single molecule. <strong>Three <\/strong>main bispecific antibody fragment formats are <strong>Bispecific T-cell engager <\/strong>(BiTE), <strong>Dual-affinity re-targeting proteins<\/strong> (DARTs), and <strong>Tandem diabodies <\/strong>(TandAbs).<\/p>\n\n\n\n<p>While most are approved for cancer treatment, specifically for conditions like multiple myeloma and DLBCL, few, including <a href=\"https:\/\/www.delveinsight.com\/blog\/hemlibra-for-hemophilia-a-treatment\"><strong>HEMLIBRA<\/strong><\/a><strong> <\/strong>and <strong>VABYSMO<\/strong>, have been sanctioned for non-cancer uses such as hemophilia A, wet age-related macular degeneration, and diabetic macular edema. Additionally, <strong>KIMMTRAK<\/strong>, another bispecific agent, has gained approval for treating uveal melanoma.<\/p>\n\n\n\n<p>In addition, in the past few years, there have been significant breakthroughs in cancer therapy within the pharmaceutical field, particularly with the emergence of bispecific antibodies as a leading edge of progress. A significant achievement in this regard was the approval by the FDA of <strong>BLINCYTO<\/strong>, the pioneering bispecific antibody aimed at treating relapsed or refractory B-cell acute lymphoblastic leukemia, which targets CD19 X CD3.The approval of BLINCYTO marked a pivotal moment in the research and development landscape of bispecific antibodies. With this therapy, <strong>Amgen <\/strong>has fortified its position in treating acute lymphoblastic leukemia. Looking ahead, Amgen aims to broaden its reach by venturing into first-line consolidation treatment and addressing patients who can benefit from chemotherapy reduction. Furthermore, the company is actively working on a subcutaneous formulation of BLINCYTO to ensure its sustained presence in the market.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"397\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100957\/1-2-1-1024x397.png\" alt=\"Market size for EPKINLY\/TEPKINLY, COLUMVI, and ORDSPONO in DLBCL in the 7MM (2020-2034)\" class=\"wp-image-32420\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100957\/1-2-1-1024x397.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100957\/1-2-1-300x116.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100957\/1-2-1-150x58.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100957\/1-2-1-768x298.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100957\/1-2-1-1536x595.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100957\/1-2-1-2048x794.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>RYBREVANT <\/strong>boasts superior safety profiles compared to the now-withdrawn <strong>EXKIVITY<\/strong>, particularly in patients with EGFR mutations involving exon 20 insertion. In September 2024, the FDA approved RYBREVANT with chemotherapy (carboplatin and pemetrexed) for adults with advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R mutations, whose disease progressed after EGFR TKI treatment. It also received FDA and European Commission approval, in combination with LAZCLUZE, for first-line treatment of advanced NSCLC, supported by Phase III PALOMA-3 results. The European Commission extended approval for a subcutaneous formulation of RYBREVANT with LAZCLUZE. Additionally, RYBREVANT is under investigation in the Phase III ORIGAMI-2 trial for colorectal cancer. Further, there are plans to broaden its application to target EGFR NSCLC, potentially positioning it as a competitor to <strong>TAGRISSO <\/strong>in the future.<\/p>\n\n\n\n<p><strong>TECVAYLI<\/strong>,<strong> ELREXFIO<\/strong>, and TALVEY targeting BCMAxCD3, BCMA X CD3, and&nbsp; GPRC5D xCD3 T-cell engagers, respectively, for the treatment of adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy. TECVAYLI was approved in 2022, while ELREXFIO and TALVEY were approved in 2023 by the FDA.<\/p>\n\n\n\n<p><strong>LUNSUMIO<\/strong>, a bispecific CD20-directed CD3 T-cell engager indicated for treating adult patients with relapsed or refractory follicular lymphoma after the FDA approved two or more lines of systemic therapy in 2022.<\/p>\n\n\n\n<p><strong>EPKINLY<\/strong> and <strong>COLUMVI<\/strong> are bispecific CD20-directed CD3 T-cell engagers approved by the FDA in 2023 for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified (DLBCL, NOS), or Large B-cell Lymphoma (LBCL) originating from follicular lymphoma, following two or more lines of systemic therapy.<strong>ORDSPONO<\/strong> was approved by the EU (2024) for treating relapsed\/refractory follicular lymphoma and DLBCL after two or more lines of systemic therapy. In February 2025, the FDA accepted the resubmission of the Biologics License Application (BLA) for ORDSPONO, aimed at treating relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. The FDA&#8217;s target action date for a decision is July 30, 2025.<\/p>\n\n\n\n<p>In November 2024, <strong>ZIIHERA<\/strong> received FDA approval for intravenous use in adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC), as confirmed by an FDA-approved test. This makes it the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the US. The approval was granted under the accelerated pathway based on findings from the HERIZON-BTC-01 clinical trial, which reported a 52% objective response rate and a median duration of response of 14.9 months, as assessed by Independent Central Review (ICR). It is also being explored in various other tumor types, including ongoing Phase III trials for Gastroesophageal Adenocarcinomas (GEA) and metastatic Breast Cancer (mBC).<\/p>\n\n\n\n<p><strong>BIZENGRI<\/strong> was approved by the FDA in 2024 for adults with pancreatic adenocarcinoma and NSCLC that are advanced, unresectable, or metastatic and harbor NRG1 gene fusions.<\/p>\n\n\n\n<p><strong>IMDELLTRA<\/strong>, a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager indicated for the treatment of adult patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy, was approved by the FDA in 2024.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-promising-bispecific-and-trispecific-antibodies-in-the-pipeline\"><span class=\"ez-toc-section\" id=\"Promising_Bispecific_and_Trispecific_Antibodies_in_the_Pipeline\"><\/span>Promising Bispecific and Trispecific Antibodies in the Pipeline<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Bispecific antibodies have gained significant attention, whereas trispecific antibodies remain largely unexplored. Most companies are still in the initial phases of research and development. <strong>Sanofi and Johnson &amp; Johnson<\/strong> stand out for their ambitious efforts in this area, with several projects underway. In contrast, many other companies have only one trispecific antibody in their developmental pipeline. The majority of the upcoming key players are focusing on oncology indications; only a few,<strong> <\/strong>such as<strong> AstraZeneca<\/strong>, are active in the non-oncology space.&nbsp;<\/p>\n\n\n\n<p>The promising <a href=\"https:\/\/www.delveinsight.com\/report-store\/bispecifics-trispecifics-competitive-landscape-and-market-forecast\">bispecific antibodies in the pipeline<\/a> include <strong>Ivonescimab (Akeso\/Summit Therapeutics), Zenocutuzumab and Petosemtamab (Merus), and Cevostamab (Roche), Volrustomig and Rilvegostomig (AstraZeneca), DR-0201 (Dren Bio<\/strong>),&nbsp; among others.<\/p>\n\n\n\n<p>In March 2025, Sanofi and Dren Bio had entered into a definitive agreement under which Sanofi had agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies.<\/p>\n\n\n\n<p><strong>Ivonescimab<\/strong>, also referred to as <strong>SMT112 <\/strong>in the US, Canada, Europe, and Japan, and AK112 in China and Australia, is a new investigational bispecific antibody targeting PD-1 and VEGF. Discovered by <strong>Akeso<\/strong>, Ivonescimab is currently undergoing multiple Phase III clinical trials. Summit and Akeso joined forces in December 2022 through a collaboration and licensing agreement for Ivonescimab. The Company has launched Phase III clinical trials for ivonescimab in NSCLC, including the HARMONi study for EGFR-mutated advanced\/metastatic NSCLC and HARMONi-3 for first-line metastatic NSCLC with chemotherapy. Additionally, the HARMONi-7 study is investigating ivonescimab monotherapy in first-line metastatic NSCLC patients with high PD-L1 expression. In October 2024, Summit Therapeutics announced the completion of enrollment in the HARMONi clinical trial, a multi-regional Phase III study comparing ivonescimab plus platinum-doublet chemotherapy to placebo plus platinum-doublet chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC.<\/p>\n\n\n\n<p><strong>Petosemtamab<\/strong>, or MCLA-158, is a Biclonics low-fucose human full-length IgG1 antibody targeting&nbsp; EGFR and LGR5. Petosemtamab was granted Breakthrough Therapy designation by the US FDA for 1L PD-L1 positive head and neck squamous cell carcinoma. The drug is also being investigated in 1L, 2L, and 3L&nbsp; metastatic colorectal cancer (mCRC).<\/p>\n\n\n\n<p>In addition to these bispecific antibodies, the promising <a href=\"https:\/\/www.delveinsight.com\/report-store\/bispecifics-trispecifics-competitive-landscape-and-market-forecast\">trispecific antibodies in the pipeline<\/a> include <strong>GB263T (Genor Biopharma), and SAR442257 (Sanofi)<\/strong>, <strong>MK-6070 (formerly HPN328) <\/strong>and<strong> MK-3000&nbsp; (Merck)<\/strong>, <strong>SIM0500 (Jiangsu Simcere Pharmaceutical)<\/strong>, among others. The anticipated launch of bispecific and trispecific antibodies is poised to revolutionize targeted therapy in biomedicine. These innovative antibodies hold the promise of enhanced efficacy and precision by simultaneously targeting multiple disease-associated molecules, potentially leading to improved treatment outcomes and expanded therapeutic options for patients across various medical conditions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bispecific-and-trispecific-antibodies-future-directions\"><span class=\"ez-toc-section\" id=\"Bispecific_and_Trispecific_Antibodies_Future_Directions\"><\/span>Bispecific and Trispecific Antibodies: Future Directions<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Bispecific and trispecific antibodies are redefining the landscape of targeted therapies, offering unmatched precision, adaptability, and the potential to address complex disease mechanisms. According to DelveInsight\u2019s analysis, the bispecific antibody market in oncology across the <strong>7MM (US, EU4, Japan) <\/strong>reached approximately <strong>USD 1.5 billion<\/strong> in <strong>2024<\/strong>, and is poised for significant growth over the forecast period of 2024\u20132034.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"310\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100756\/Market-Size-of-Bispecific-Antibodies-in-DLBCL-in-2034-1024x310.png\" alt=\"Market-Size-of-Bispecific-Antibodies-in-DLBCL-in-2034\" class=\"wp-image-32419\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100756\/Market-Size-of-Bispecific-Antibodies-in-DLBCL-in-2034-1024x310.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100756\/Market-Size-of-Bispecific-Antibodies-in-DLBCL-in-2034-300x91.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100756\/Market-Size-of-Bispecific-Antibodies-in-DLBCL-in-2034-150x45.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100756\/Market-Size-of-Bispecific-Antibodies-in-DLBCL-in-2034-768x232.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100756\/Market-Size-of-Bispecific-Antibodies-in-DLBCL-in-2034-1536x465.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/11100756\/Market-Size-of-Bispecific-Antibodies-in-DLBCL-in-2034-2048x620.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>While hematologic malignancies currently dominate the bispecific antibody market, the therapeutic focus is rapidly shifting toward solid tumors, including non-small cell lung cancer (NSCLC), which is expected to capture a substantial market share in the coming years. Notably, <strong>RYBREVANT<\/strong> is anticipated to be a major growth driver, with projected revenues nearing <strong>USD 3.6 billion by 2034<\/strong>.<\/p>\n\n\n\n<p>Looking forward, research and development in this field are intensifying to overcome current limitations and broaden clinical utility. Innovations in antibody engineering, computational modeling, and high-throughput screening are enabling the creation of next-generation biologics with superior efficacy, specificity, and safety. These advancements are set to expand the therapeutic potential of bispecific and trispecific antibodies across oncology and beyond, heralding a new era in precision medicine.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/bispecifics-market-forecast\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/09150819\/Bispecifics-and-Trispecifics-Market-Forecast-1024x194.png\" alt=\"Bispecifics-and-Trispecifics-Market-Forecast\" class=\"wp-image-29952\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/09150819\/Bispecifics-and-Trispecifics-Market-Forecast-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/09150819\/Bispecifics-and-Trispecifics-Market-Forecast-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/09150819\/Bispecifics-and-Trispecifics-Market-Forecast-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/09150819\/Bispecifics-and-Trispecifics-Market-Forecast-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/09150819\/Bispecifics-and-Trispecifics-Market-Forecast-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/09150819\/Bispecifics-and-Trispecifics-Market-Forecast.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><figcaption class=\"wp-element-caption\">Bispecifics-and-Trispecifics-Market-Forecast<\/figcaption><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>CAR-T cell therapy has revolutionized the treatment of blood cancers, earning regulatory approval and delivering impressive results in hematologic malignancies. However, its success has not yet translated to solid tumors, where it continues to face significant challenges and limited long-term efficacy. As a result, ongoing CAR-T development remains largely focused on blood cancers. In contrast, [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":27981,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19285,19286,810,21821,21718,22089,20717,19901,22097],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-27979","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-bispecific-antibody","tag-bispecific-antibody-clinical-trials","tag-car-t","tag-car-t-cell-therapies","tag-car-t-cell-therapies-for-cancer","tag-car-t-cell-therapy-2","tag-cd20xcd3-bispecific-antibody","tag-hemlibra","tag-trispecific-antibody","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Potential of Bispecific and Trispecific Antibodies: Beyond CAR-T<\/title>\n<meta name=\"description\" content=\"Bispecific and trispecific antibodies represent paradigm shift in targeted therapy, offering precision &amp; versatility in disease treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Potential of Bispecific and Trispecific Antibodies: Beyond CAR-T\" \/>\n<meta property=\"og:description\" content=\"Bispecific and trispecific antibodies represent paradigm shift in targeted therapy, offering precision &amp; versatility in disease treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T04:42:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-11T04:42:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/13143057\/bispecific-and-trispecific-antibodies.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Potential of Bispecific and Trispecific Antibodies: Beyond CAR-T","description":"Bispecific and trispecific antibodies represent paradigm shift in targeted therapy, offering precision & versatility in disease treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies","og_locale":"en_US","og_type":"article","og_title":"Potential of Bispecific and Trispecific Antibodies: Beyond CAR-T","og_description":"Bispecific and trispecific antibodies represent paradigm shift in targeted therapy, offering precision & versatility in disease treatment.","og_url":"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-06-10T04:42:12+00:00","article_modified_time":"2025-06-11T04:42:32+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/13143057\/bispecific-and-trispecific-antibodies.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies","url":"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies","name":"Potential of Bispecific and Trispecific Antibodies: Beyond CAR-T","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/13143057\/bispecific-and-trispecific-antibodies.png","datePublished":"2025-06-10T04:42:12+00:00","dateModified":"2025-06-11T04:42:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Bispecific and trispecific antibodies represent paradigm shift in targeted therapy, offering precision & versatility in disease treatment.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/bispecific-and-trispecific-antibodies#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/13143057\/bispecific-and-trispecific-antibodies.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/13143057\/bispecific-and-trispecific-antibodies.png","width":466,"height":284,"caption":"bispecific-and-trispecific-antibodies"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/13143057\/bispecific-and-trispecific-antibodies-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">bispecific antibody<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">bispecific antibody clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CAR-T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CAR-T cell therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CAR-T cell therapies for cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CAR-T cell therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CD20XCD3 Bispecific Antibody<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">HEMLIBRA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Trispecific Antibody<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">bispecific antibody<\/span>","<span class=\"advgb-post-tax-term\">bispecific antibody clinical trials<\/span>","<span class=\"advgb-post-tax-term\">CAR-T<\/span>","<span class=\"advgb-post-tax-term\">CAR-T cell therapies<\/span>","<span class=\"advgb-post-tax-term\">CAR-T cell therapies for cancer<\/span>","<span class=\"advgb-post-tax-term\">CAR-T cell therapy<\/span>","<span class=\"advgb-post-tax-term\">CD20XCD3 Bispecific Antibody<\/span>","<span class=\"advgb-post-tax-term\">HEMLIBRA<\/span>","<span class=\"advgb-post-tax-term\">Trispecific Antibody<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 months ago","modified":"Updated 10 months ago"},"absolute_dates":{"created":"Posted on Jun 10, 2025","modified":"Updated on Jun 11, 2025"},"absolute_dates_time":{"created":"Posted on Jun 10, 2025 10:12 am","modified":"Updated on Jun 11, 2025 10:12 am"},"featured_img_caption":"bispecific-and-trispecific-antibodies","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=27979"}],"version-history":[{"count":5,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27979\/revisions"}],"predecessor-version":[{"id":32421,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27979\/revisions\/32421"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/27981"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=27979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=27979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=27979"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=27979"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=27979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}